Bladder transitional cell carcinoma stage 0 is the earliest form of this disease, where cancer cells are found only in the innermost lining of the bladder and have not yet invaded deeper layers. Treatment focuses on removing these early tumors while preventing them from returning or progressing to more invasive forms. The approach combines surgical removal with additional therapies to reduce recurrence risk, and because this cancer frequently comes back, ongoing monitoring becomes a crucial part of long-term care.

Understanding Treatment Goals for the Earliest Bladder Cancer

When bladder cancer is caught at stage 0, the primary goal of treatment is to completely remove the cancer from the bladder while preserving normal bladder function. This stage is also called non-invasive bladder cancer because the disease hasn’t yet grown into the deeper muscle layers of the bladder wall. Doctors classify stage 0 into two subtypes: stage 0a, which appears as small growths extending into the bladder space, and stage 0is, known as carcinoma in situ, which appears as flat patches on the bladder lining.^[1][2]

Treatment decisions depend on several factors that help doctors predict how the cancer might behave. These include whether the cancer is classified as low risk, intermediate risk, or high risk for coming back or progressing. The size and number of tumors, along with how abnormal the cells appear under a microscope (the grade), all influence the treatment plan. Some people with very low-risk cancer may need only surgery followed by careful watching, while those with high-risk features typically receive additional treatments to lower the chance of recurrence.^[3][4]

The medical community recognizes that stage 0 bladder cancer, despite being highly treatable when discovered early, has a strong tendency to return. Studies show that between 50 and 75 percent of patients experience cancer recurrence after initial treatment, though these returning cancers are usually of the same stage and can be treated successfully again. This pattern means that treatment isn’t a single event but rather an ongoing process that may continue for years.^[9][10]

Standard Surgical Treatment: Removing Cancer Through the Urethra

The foundation of treatment for stage 0 bladder cancer is a surgical procedure called transurethral resection, often abbreviated as TUR or TURBT (transurethral resection of bladder tumor). This operation serves both as a diagnostic tool and as the main treatment method. During the procedure, a surgeon inserts a thin, lighted tube called a cystoscope through the urethra—the channel through which urine normally exits the body—and into the bladder. Through this tube, the surgeon can see the inside of the bladder and remove cancer tissue using special instruments or destroy it with heat (a technique called fulguration).^[9][10]

The advantage of transurethral resection is that it requires no external incisions. Patients typically recover more quickly than they would from traditional surgery involving cuts through the abdomen. The procedure allows doctors to remove tissue samples that pathologists examine under microscopes to determine the exact type and grade of cancer. Sometimes, doctors recommend a second TUR procedure if the first one didn’t remove enough tissue or didn’t include a sample from the muscle layer beneath the tumor. This repeat procedure helps ensure complete removal and accurate staging.^[12][13]

For most people with stage 0 cancer, transurethral resection alone may be sufficient to remove all visible cancer. However, because microscopic cancer cells may remain in the bladder lining even after surgery appears successful, additional treatments are usually recommended. The surgical procedure itself carries relatively few risks, though patients may experience some blood in the urine or discomfort during urination for a short time after the operation. Serious complications, such as bladder perforation or significant bleeding, occur rarely.^[7][15]

Intravesical Therapy: Delivering Medicine Directly Into the Bladder

Intravesical therapy means placing medication directly into the bladder rather than taking it by mouth or receiving it through an intravenous line. This approach allows high concentrations of medicine to reach bladder tissue while minimizing effects on the rest of the body. For stage 0 bladder cancer, intravesical therapy serves as an important follow-up to surgery, helping to destroy any remaining cancer cells and reduce the likelihood of recurrence.^[10][13]

There are two main types of intravesical therapy: chemotherapy and immunotherapy. Intravesical chemotherapy uses cancer-killing drugs, most commonly mitomycin or gemcitabine. These medications are placed into the bladder through a thin catheter inserted into the urethra. The medication remains in the bladder for a period of time, usually one to two hours, before being drained out. Many patients receive a single dose of intravesical chemotherapy within 24 hours after their initial surgery, which has been shown to lower recurrence rates.^[10][17]

The other form of intravesical therapy uses a substance called BCG, which stands for bacillus Calmette-Guérin. BCG is not actually a chemotherapy drug but rather a weakened form of bacteria related to tuberculosis. When placed in the bladder, BCG triggers a local immune response that helps the body’s defense system recognize and attack cancer cells. BCG has become the preferred treatment for people with intermediate-risk or high-risk stage 0 bladder cancer because it has been shown to be particularly effective at preventing cancer from returning or progressing to more invasive forms.^[9][12]

The schedule for intravesical therapy varies based on risk level and the type of treatment used. For people with low-risk cancer, a single dose of chemotherapy at the time of surgery may be all that’s needed. Those with intermediate-risk cancer typically receive weekly treatments for six weeks, a regimen called induction therapy. If cancer is classified as high-risk, the six-week induction course is often followed by maintenance therapy, which means continuing treatments at less frequent intervals—perhaps once a month or once every few months—for up to three years. This extended treatment schedule aims to keep the immune system vigilant against any returning cancer cells.^[10][17]

Side effects from intravesical therapy are generally limited to the bladder and urinary system. People receiving these treatments commonly experience increased urgency to urinate, more frequent urination, or a burning sensation when urinating. These symptoms usually improve within a few days after each treatment. With BCG specifically, some people develop blood in their urine or experience bladder spasms. Drinking plenty of fluids helps flush the bladder and can reduce irritation.^[25]

Surveillance: The Critical Role of Regular Follow-Up

After completing initial treatment, people with stage 0 bladder cancer enter a phase of close monitoring called surveillance. This isn’t treatment in the traditional sense but rather a systematic approach to watching for any signs that cancer might be returning. Surveillance is essential because even after successful removal and additional therapy, bladder cancer at this stage has a high tendency to recur. Regular examinations allow doctors to detect recurrences when they’re still small and easier to treat.^[10][21]

The main surveillance tool is cystoscopy, the same type of examination used during the initial diagnosis. During a surveillance cystoscopy, the doctor inserts a thin, flexible tube with a camera through the urethra to directly view the inside of the bladder. This allows detection of any new growths or abnormal areas. The frequency of these examinations depends on cancer risk level—people with low-risk cancer might need cystoscopy every year or less often, while those with high-risk features typically need examinations every three months initially, with the interval gradually lengthening if no cancer reappears.^[9][13]

Along with cystoscopy, doctors may order urine tests to look for cancer cells or substances that cancer cells release. These tests, called urinary cytology, examine urine under a microscope to identify abnormal cells. While not as sensitive as cystoscopy for detecting recurrence, urinary cytology can sometimes find cancer that isn’t yet visible during cystoscopy. Some medical centers are beginning to use newer urine-based tests that look for specific molecular markers of cancer, though these are still being evaluated for routine use in surveillance.^[9][20]

Living with the need for regular surveillance can be emotionally challenging. Many people report anxiety before follow-up appointments, worried about what the tests might reveal. Understanding that surveillance is a protective measure—designed to catch any problems when they’re most manageable—can help reduce this “scanxiety.” Support groups and counseling services can provide valuable emotional support during the surveillance period, helping people maintain a positive outlook while staying vigilant about their health.^[20]

When Standard Treatment Isn’t Enough

In some situations, stage 0 bladder cancer doesn’t respond adequately to transurethral resection and intravesical therapy, or it returns repeatedly despite these treatments. When cancer recurs multiple times or doesn’t respond to BCG treatment, doctors classify it as very high-risk or BCG-unresponsive disease. At this point, more aggressive treatment options need to be considered to prevent the cancer from progressing to muscle-invasive disease.^[10][21]

One option is cystectomy, which means surgical removal of part or all of the bladder. A radical cystectomy removes the entire bladder along with nearby lymph nodes and, in men, the prostate and seminal vesicles, or in women, the uterus, ovaries, and part of the vagina. While this may seem drastic for cancer that hasn’t invaded the muscle, it can be lifesaving for people whose cancer persists despite other treatments or who have widespread carcinoma in situ that doesn’t respond to BCG.^[9][17]

After bladder removal, surgeons create a new way for urine to exit the body, a procedure called urinary diversion. There are several approaches: one creates a new bladder-like reservoir inside the body using a piece of intestine, another directs urine into a small pouch that collects it outside the body, and a third creates a connection that allows urine to drain into the colon. Each method has advantages and disadvantages, and the choice depends on individual factors including age, overall health, and personal preferences. While bladder removal significantly impacts quality of life, many people adapt successfully and continue to live full, active lives.^[9]

Experimental Approaches Being Studied in Clinical Trials

Researchers continue to explore new treatment strategies for stage 0 bladder cancer, particularly for people whose disease doesn’t respond to BCG or who cannot tolerate BCG treatment. Clinical trials—carefully controlled research studies—are testing several promising approaches that may offer alternatives to bladder removal for people with difficult-to-treat early-stage disease.

One area of investigation involves different forms of immunotherapy beyond BCG. Scientists are studying checkpoint inhibitors, drugs that help the immune system recognize and attack cancer cells more effectively. These medications, which include drugs like pembrolizumab and nivolumab, have shown promise in treating muscle-invasive and metastatic bladder cancer, and researchers are now evaluating whether they might also help people with high-risk non-muscle-invasive disease that hasn’t responded to BCG. Some trials are testing these drugs given intravenously, while others are exploring intravesical administration directly into the bladder.^[10]

Another experimental approach involves combinations of different intravesical therapies. Some clinical trials are testing whether combining chemotherapy drugs with each other, or with immune-stimulating agents other than BCG, might improve response rates. For example, researchers are investigating whether combining gemcitabine with other medications can create a more effective treatment than either drug alone. Other studies are examining whether heating the chemotherapy solution before placing it in the bladder—a technique called hyperthermia—increases its cancer-killing ability.

Gene therapy represents another frontier in bladder cancer treatment research. Scientists are developing ways to deliver genetic material directly into bladder cells to make them more susceptible to treatment or to trigger their self-destruction if they become cancerous. While these approaches remain experimental and are still in early-phase clinical trials, they represent the kind of innovative thinking that may lead to better treatments in the future.

Participation in clinical trials gives people access to potentially beneficial new treatments before they become widely available. Trials also contribute to medical knowledge that will help future patients. People interested in clinical trials should discuss this option with their healthcare team, who can help determine whether any appropriate trials are available and whether participation would be suitable given individual circumstances. Information about ongoing trials can be found through resources like the National Cancer Institute’s clinical trials database and cancer center websites.^[10]

Most common treatment methods

• Transurethral resection (TUR/TURBT)
  • Surgical removal of bladder tumors through the urethra using a cystoscope
  • Serves as both diagnostic procedure and primary treatment for stage 0 cancer
  • May include fulguration (destruction of cancer tissue with heat)
  • Sometimes repeated if initial surgery doesn’t remove sufficient tissue or muscle layer sample
• Intravesical chemotherapy
  • Chemotherapy drugs placed directly into the bladder through a catheter
  • Commonly uses mitomycin or gemcitabine
  • Single dose often given within 24 hours after surgery
  • May continue weekly for six weeks for intermediate-risk cancer
  • Can extend to maintenance therapy lasting up to one year
• Intravesical BCG immunotherapy
  • Uses bacillus Calmette-Guérin bacteria to stimulate immune response against cancer
  • Preferred treatment for intermediate and high-risk stage 0 bladder cancer
  • Induction therapy consists of weekly treatments for six weeks
  • Maintenance therapy may continue for up to three years for high-risk disease
  • More effective than chemotherapy at preventing progression to invasive cancer
• Surveillance with cystoscopy
  • Regular bladder examinations using a camera inserted through the urethra
  • Frequency depends on risk level: every three months for high-risk, less often for low-risk
  • Combined with urinary cytology to detect cancer cells in urine
  • Essential for detecting recurrence when it’s most treatable
• Cystectomy
  • Surgical removal of part or all of the bladder
  • Radical cystectomy removes entire bladder and nearby organs
  • Considered for cancer that doesn’t respond to BCG or recurs repeatedly
  • Requires urinary diversion surgery to create new method for urine storage and elimination
  • May include creation of internal reservoir (neobladder), external collection pouch, or connection to colon

Lifestyle Considerations After Treatment

Beyond medical treatments, certain lifestyle choices may influence the course of bladder cancer and overall health during the treatment and surveillance periods. While these measures don’t replace standard medical care, they can complement treatment and potentially reduce recurrence risk while improving general well-being.

Smoking cessation stands out as the most important lifestyle change for anyone with bladder cancer. Cigarette smoke is thought to cause approximately half of all bladder cancers, and continuing to smoke after diagnosis may increase the risk of cancer recurrence and progression. The harmful chemicals in tobacco smoke must be filtered by the kidneys and pass through the bladder, exposing bladder tissue to carcinogens. Quitting smoking is challenging, but healthcare providers can offer support through medications, counseling, and smoking cessation programs.^[20]

Staying well-hydrated helps protect the bladder by diluting potentially harmful substances in urine and promoting regular bladder emptying. Healthcare providers typically recommend drinking six to eight glasses of water daily. This practice may lower the risk of bladder problems and helps flush the bladder, which can be particularly beneficial during and after intravesical therapy when irritation is common.^[20]

A diet rich in fruits, vegetables, and whole grains provides nutrients that support overall health and may help the bladder remain healthy. While no specific diet has been proven to prevent bladder cancer recurrence, eating a variety of colorful vegetables and fruits ensures intake of vitamins, minerals, and antioxidants that support the body’s natural defense mechanisms. A Mediterranean-style diet—emphasizing plant foods, whole grains, fish, and olive oil while limiting red meat—has been associated with better health outcomes for many conditions, including cancer.^[20][25]

Regular physical activity contributes to better overall health and may improve outcomes for people with cancer. Exercise helps manage treatment side effects such as fatigue and can reduce anxiety and improve mood. Even moderate activity, such as 30 minutes of walking most days of the week, provides benefits. People should discuss appropriate exercise programs with their healthcare team, starting slowly and gradually increasing activity levels as tolerated.^[20]